REGENXBIO Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
REGENXBIO Inc. (RGNX) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $61.12 million as of 2019-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2021-03-01
- 2019-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $61.12M.
- 2019-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $61.12M.
- 2019-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $61.12M.
- 2019-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $61.12M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value as first filed |
|---|---|---|
| 2019-12-31 | $61.12M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $61.12M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $61.12M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $61.12M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $298.41M 10-K · filed 2020-02-26 | |
| 2018-03-31 | $127.30M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $109.24M 10-K · filed 2019-02-27 | $109.20M 10-K · filed 2018-03-06 |
| 2017-09-30 | $109.00M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $127.20M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $89.90M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $102.50M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $40.51M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $48.72M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $74.71M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $155.50M 10-K · filed 2017-03-07 | $155.49M 10-K · filed 2016-03-03 |
| 2015-09-30 | $18.01M 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |